Logo image
Back
Hydrocortisone Reduces 28-day Mortality in Septic Patients: A Systemic Review and Meta-analysis
Journal article   Open access   Peer reviewed

Hydrocortisone Reduces 28-day Mortality in Septic Patients: A Systemic Review and Meta-analysis

Waqas J Siddiqui, Praneet Iyer, Ghulam Aftab, FNU Zafrullah, Muhammad A Zain, Kadambari Jethwani, Rabia Mazhar, Usman Abdulsalam, Abbas Raza, Muhammad O Hanif, …
Curēus (Palo Alto, CA), v 11(6), pp e4914-e4914
17 Jun 2019
DOI: https://doi.org/10.7759/cureus.4914
PMID: 31423390
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://www.cureus.com/articles/19399-hydrocortisone-reduces-28-day-mortality-in-septic-patients-a-systemic-review-and-meta-analysis.pdfView
Published, Version of Record (VoR) Open
url
https://doi.org/10.7759/cureus.4914View
Published, Version of Record (VoR) Open

Abstract

fludrocortisone hydrocortisone Infectious Disease Internal Medicine meta-analysis mortality Other sepsis septic shock
The goal of this study was to determine the utility of hydrocortisone in septic shock and its effect on mortality. We performed a systematic search from inception until March 01, 2018, according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines comparing hydrocortisone to placebo in septic shock patients and selected studies according to our pre-defined inclusion and exclusion criteria. Four reviewers extracted data into the predefined tables in the Microsoft Excel (Microsoft Corp., New Mexico, US) sheet. We used RevMan software to perform a meta-analysis and draw Forest plots. We used a random effects model to estimate risk ratios. A two-sided p-value of ≤ 0.05 was considered statistically significant. A total of five randomized control trials (RCTs) with 5,838 patients were included in our analysis. The primary outcome was mortality at 28 days. Secondary outcomes were intensive care unit (ICU) and in-hospital mortality, mortality at 90 days and one year, reversal of shock, intensive care unit (ICU) and hospital length of stay, incidence of superinfections, and incidence of limb and/or cerebral ischemia. The 28-day mortality was significantly reduced with hydrocortisone, 808 vs. 880 with placebo, Risk Ratio (RR)=0.92, confidence interval (CI) =0.85-0.99, p=0.04, I 2 =0%. There was no difference in ICU mortality (RR=0.93, CI=0.81-1.08), in-hospital mortality (RR=0.95, CI=0.84-1.08), 90-day mortality (RR=0.93, CI=0.84-1.02, p=0.10), and one-year mortality (RR=0.97, CI=0.84-1.12). Superinfections were significantly common with hydrocortisone, RR=1.16, CI=1.05-1.28, p=0.003. In conclusion, the use of hydrocortisone showed a significant reduction in mortality at 28 days and a trend toward reduced ICU mortality. This mortality reduction was observed at the cost of significantly higher superinfections.

Metrics

8 Record Views
5 citations in Web of Science

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
International collaboration
Web of Science research areas
Critical Care Medicine
Logo image